Clinical trial · Interventional
Does Tranexamic Acid Administration Reduce Blood Loss During Head and Neck Surgery?
NCT00147862CI-TRIAL-00000598completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To Study whether infusion of Tranexamic Acid (a synthetic antifibrinolytic agent) reduces blood loss during head and neck surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Neoplasms | Head and Neck Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tranexamic Acid | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Administration of tranexamic acid reduces perioperative blood loss and thus,
- measure
- Requirement for replacement of blood in head and neck surgeries
Secondary outcomes (2)
- measure
- To observe procoagulant effects leading to complications, if any.
- measure
- Cost effectiveness of the drug in terms of savings on blood transfusion requirements.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * All eligible previously untreated patients with resectable squamous cell carcinoma of the oral cavity * Undergoing composite resection of the mandible along with neck dissection and requiring reconstructive procedures in the form of pedicled flaps. * Patients who agree to participate by giving informed consent. Exclusion Criteria: * Coagulopathy form any cause (Abnormal coagulogram - prothrombin time (PT) \> 18 seconds or partial prothrombin time (PTT) \> 50 seconds, recent (\<5 days) acetylsalicylic acid ingestion, anticoagulant therapy (heparin, 4 hours preoperative or warfarin, 3 days preoperatively). * Pre-existing renal dysfunction (serum creatinine 200 mmol/L), * Known allergy to tranexamic acid, * Peripheral vascular disease.
References
Publications (0)
Data not yet available
No reference posted for this study.